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STUDY PROTOCOL

Open Access

Test of a workforce development
intervention to expand opioid use disorder
treatment pharmacotherapy prescribers:
protocol for a cluster randomized trial
Todd Molfenter1* , Hannah K. Knudsen4, Randy Brown2, Nora Jacobson3, Julie Horst1, Mark Van Etten1,
Jee-Seon Kim5, Eric Haram1, Elizabeth Collier6, Sanford Starr7, Alexander Toy1 and Lynn Madden1

Abstract
Background: Overdoses due to non-medical use of prescription opioids and other opiates have become the leading
cause of accidental deaths in the USA. Buprenorphine and extended-release naltrexone are key evidence-based
pharmacotherapies available to addiction treatment providers to address opioid use disorder (OUD) and prevent
overdose deaths. Treatment organizations’ efforts to provide these pharmacotherapies have, however, been stymied by
limited success in recruiting providers (physicians, nurse practitioners, and physician assistants) to prescribe these
medications. Historically, the addiction treatment field has not attracted physicians, and many barriers to implementing
OUD pharmacotherapy exist, ranging from lack of confidence in treating OUD patients to concerns regarding
reimbursement. Throughout the USA, the prevalence of OUD far exceeds the capacity of the OUD pharmacotherapy
treatment system. Poor access to OUD pharmacotherapy prescribers has become a workforce development need for
the addiction treatment field and a significant health issue.
Methods: This cluster randomized controlled trial (RCT) is designed to increase buprenorphine and extended-release
naltrexone treatment capacity for OUD. The implementation intervention to be tested is a bundle of OUD
pharmacotherapy capacity building practices called the Prescriber Recruitment Bundle (PRB), which was developed and
piloted in a previous statewide buprenorphine implementation study. For this cluster RCT, organizational sites will be
recruited and then randomized into one of two arms: (1) control, with treatment as usual and access to a website with
PRB resources, or (2) intervention, with organizations implementing the PRB using the Network for the Improvement of
Addiction Treatment organizational change model over a 24-month intervention period and a 10-month sustainability
period. The primary treatment outcomes for each organizational site are self-reported monthly counts of
buprenorphine slots, extended-release naltrexone capacity, number of buprenorphine patients, and number of
extended-release naltrexone patients.
This trial will be conducted in Florida, Ohio, and Wisconsin, resulting in 35 sites in each arm, for a total sample size of
70 organizations.
Discussion: This study addresses three issues of substantial public health significance: (1) the pressing opioid misuse
epidemic, (2) the low uptake of OUD treatment pharmacotherapies, and (3) the need to increase prescriber
participation in the addiction treatment workforce.
(Continued on next page)
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Background
Overdoses due to non-medical use of prescription opioids and other opiates have become the leading cause of
accidental deaths in the USA [1]. Opioid use disorder
(OUD) pharmacotherapies are a key evidence-based
intervention available to specialty addiction treatment
organizations to address the increase in OUDs and reduce
overdose deaths [2–4]. This study focuses on two of these
pharmacotherapies, buprenorphine and extended-release
naltrexone. Buprenorphine is an opioid agonist therapy that
binds to the opioid receptor to reduce the effects of opioids.
Buprenorphine enhances retention in treatment and
reduces self-reported use of opioids, criminal activity, and
mortality [3, 5, 6]. Buprenorphine can only be prescribed
by health care providers who have completed training to
obtain a waiver to treat a limited number of patients [7].
Patients take the medication daily via tablet or film formulations; a longer-acting implant formulation is also available.
Extended-release naltrexone (Vivitrol®) is an opioid
antagonist medication that blocks the opioid receptor and
also has improved retention rates when compared to placebo [4, 8]. Extended-release naltrexone is typically injected
once a month at prescriber’s office location. While these
pharmacotherapies hold great promise, they are underutilized in OUD treatment. Of the 2.5 million Americans
12 years of age or older with OUDs [9], fewer than 128,000
of those attending specialty treatment programs had
treatment plans that included pharmacotherapy [10].
Treatment organizations’ efforts to provide OUD
pharmacotherapies have been hindered by limited
success in recruiting providers to prescribe these
medications. In previous studies [11], physician prescribers have expressed hesitancy to prescribe OUD
treatment pharmacotherapies due to feeling that treating OUD patients can be difficult, limited confidence
in treating OUD patients, lack of institutional support, inadequately trained staff, time constraints, poor
reimbursement rates, and regulatory barriers to OUD
pharmacotherapy [11–15]. One regulatory barrier specific to buprenorphine requires prescribers to apply
for a waiver that limits them to treating 30 patient
slots in year 1, 100 slots in year 2, and up to 275
slots per year thereafter. Legislation passed in 2016
expands prescribing privileges to advanced practice
registered nurses and physician assistants, who must
also complete training and obtain a waiver to treat a
limited number of patients [16].

These conditions have created significant barriers to
OUD treatment capacity and implementation of these
pharmacotherapies. A recent analysis found that 24.1% of
specialty treatment organizations using buprenorphine
pharmacotherapy had to turn patients away due to insufficient prescribing capacity [17]. About 43% of the US
counties have no buprenorphine prescribers; among states
and the District of Columbia, 96% had OUD rates that
exceeded their buprenorphine capacity [18].
Poor access to prescribers of OUD pharmacotherapy
has become a workforce development need in the addiction treatment field. Traditionally, organizations providing
addiction treatment services have not developed competency in recruiting prescribers; rather, they have primarily
relied on a clinical workforce of counselors. That is
quickly changing, as addiction treatment providers are
now being called upon to expand their clinical services
into physician-supported areas such as primary care,
mental health/psychiatry, and pharmacotherapy for addiction disorders. This study protocol’s aim is to address this
emerging need by testing a bundle of practices, the
Prescriber Recruitment Bundle (PRB), coupled with the
Network for the Improvement of Addiction Treatment
(NIATx) organizational change model to increase OUD
treatment pharmacotherapy workforce capacity.
The PRB was developed to address the leading barrier
to buprenorphine implementation, lack of physician prescribing capacity, as identified by 40 treatment organizations participating in the Ohio project titled “To Test a
Payer/Treatment Agency Intervention to Increase Use of
Buprenorphine.” This was a surprising finding because
lack of reimbursement for buprenorphine was expected
to be the most frequent and challenging barrier to
expanding buprenorphine use. However, as the project
proceeded and reimbursement barriers were removed,
the lack of physicians to prescribe buprenorphine
prevented its use within treatment organizations. As a
result, different interventions began to be tested to
increase buprenorphine prescriber capacity. The
successful interventions were packaged into what
became the PRB and later were tested by eight organizations in the project. The eight organizations that applied
the PRB increased buprenorphine prescribing slots by
48.3–100%. The slots, once acquired, were mostly filled
due to the pressing need for medication-assisted treatment services. The PRB pilot recruited 10 new physicians and increased buprenorphine prescribing slots
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across the eight organizations by more than twofold.
The PRB developed and piloted was limited to a pre/
post-evaluation on a convenience sample; this protocol
will describe a randomized test of the PRB.
Objectives

In this cluster randomized controlled trial (RCT), the
primary aim is to test the impact of the PRB implemented in conjunction with the NIATx organizational
change model, relative to the control, on (a) increasing
the number of buprenorphine treatment slots and
extended-release naltrexone capacity and (b) increasing
the number of patients receiving buprenorphine and
extended-release naltrexone in the participating addiction treatment organizations. A secondary aim is to test
whether the PRB affects factors likely to be associated
with prescriber recruitment, including resources
dedicated to prescriber recruitment and physicians’ job
satisfaction [19–21], and subsequently, whether these
factors mediate the effects of the PRB on key outcomes.
Lastly, qualitative methods will be used to study the context and processes that influence PRB adoption and
fidelity, to develop a deeper understanding of how the
PRB influences recruitment beyond the quantitative
study variables, and to gain knowledge of what
organizational processes contribute to successful
licensed prescriber recruitment.
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prescribing capacity. Organizations expressing the need
for greater OUD pharmacotherapy capacity were
recruited into the trial through an invitation from the
study team. Of 125 organizations indicating need for
greater OUD pharmacotherapy, 24 organizations from
Florida, 23 from Ohio, and 23 from Wisconsin agreed to
participate, for a total of 70 organizational sites (Fig. 1,
consort diagram). Thirty-five were placed in the intervention arm, and 35 were in the control arm.
Randomization and consent procedures

The first stage of the block randomization within each
state is to develop sampling matched organizations from
those that agreed to participate, based on their current
use of PRB practices (i.e., number of PRB practices being
used 0–7) and whether they were currently prescribing
buprenorphine (i.e., yes or no). As a result, 11–13
matched pairs are identified per state. For Ohio and
Wisconsin, one matched pair will have two intervention
sites to one control site, due to the overall uneven number
(n = 23). A random number generator is utilized to assign
organizations within each pair into one of the two study
conditions. Following randomization, study staff will provide University of Wisconsin Institutional Review Board
approved study information sheets to staff participants.
No visible concealment will be applied. Blinding of participants and researchers is considered logistically infeasible.

Methods

Interventions

Trial design

The PRB uses two approaches to implementation: the
NIATx organizational change model within a multiorganizational learning collaborative in the intervention
arm and online PRB resources in both study arms. The
PRB includes:

In the intervention arm of this cluster randomized trial,
the PRB will be implemented during a 24-month trial
using the evidence-based NIATx organizational change
model developed by our research center. The control
arm will only receive access to the PRB materials online
via a secure website. Organizations in the control arm
will complete all the same data collection instruments as
those in the intervention arm.
Participants

We selected the three states (FL, OH, and WI) due to
the states’ varied frequency of opioid analgesic prescribing and drug-poisoning deaths [22, 23]. These states
offered a mix of urban and rural settings, presence of
minority populations, strength of data collection and
reporting systems, and representation of both Medicaid
expansion and non-expansion states.
In all three states, recruitment began with surveying
all publicly funded organizations that are licensed to
provide addiction treatment services and have at least
100 admissions per year. The state-based addiction treatment authorities provided a list of the organizations
meeting these eligibility criteria. The survey assessed the
organizations’ interest in increasing their buprenorphine

a) Candidate identification strategies for finding
prescribers interested in prescribing OUD
pharmacotherapies. The Ohio “To Test a Payer/
Treatment Agency Intervention to Increase Use of
Buprenorphine” found the following physician
specialties to be more likely to become opioid
pharmacotherapy prescribers: (a) addiction medicine
specialists, (b) psychiatrists who are already
practicing within the organization, and (c) family
medicine and internists in the community. Similarly,
Rosenblatt et al. [24] observed that 81.9% of
physicians with a Drug Enforcement Administration
(DEA) waiver to prescribe buprenorphine came
from a combination of the psychiatry, primary care,
and addiction medicine specialties. The bundle
recommends seeking physician prescribers from
these specialties and to be aware that as of 2016,
advanced practice nurses and physician assistants
can also now prescribe buprenorphine [25].
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Fig. 1 Consort diagram. PRB Prescriber Recruitment Bundle

b) Prescriber education forum slide deck that can be
used to inform prescriber groups and stimulate
interest in OUD pharmacotherapy prescribing.
Potential prescribers are often unaware of the
practice opportunities in addiction medicine. Once
they are aware of those opportunities, they are more
likely to provide care to patients with addiction
disorders [26]. Education forums can describe
practice opportunities in the addiction field, how
physicians and other clinicians can reduce the
impact of OUDs, and give medical professionals the
opportunity to express their interest in becoming
OUD pharmacotherapy prescribers. The slide deck is
intended for use by agency staff
c) Prescriber-friendly workflow and risk-reduction
strategies that provide clinical supports to assist
prescribers with managing OUD pharmacotherapy
patients. Two concerns of potential prescribers are
that patients on opioid treatment pharmacotherapies

require added effort and that these patients present
additional clinical risk [27]. LaBelle et al. [28]
reported that the use of nurses to assist physicians
with the provision of buprenorphine treatment has
led to expanded use of this pharmacotherapy. This
strategy reduces the clinical workload on prescribers
and allows for the use of a risk management plan
based on existing clinical guidelines that also prevents
the non-medical use or diversion of buprenorphine
prescriptions [29]. Education can also be provided on
how buprenorphine side effects and mortality are low,
and side effects are less severe than other comparable
opioid treatment alternatives [3].
d) Academic detailing to recruit OUD prescribers.
Academic detailing is an evidence-based tool to
influence prescriber decision making and to recruit
OUD prescribers. Developed by Soumerai et al. [30],
academic detailing uses persuasive communication
to influence physician behavior [31, 32]. This
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approach applied to recruiting OUD pharmacotherapy prescribers includes the following steps: (1) conducting interviews to investigate baseline knowledge
of and motivations for buprenorphine treatment, (2)
defining clear educational behavioral objectives, (3)
establishing credibility by citing authoritative and
unbiased sources of information and presenting both
sides of controversial issues, (4) stimulating active
physician and clinician participation in educational
interactions, (5) using concise graphic educational
materials, (6) highlighting and repeating the essential
messages, and (7) providing positive reinforcement
during follow-up visits. Agency staff are encouraged
to use academic detailing strategies as part of physician recruitment.
e) Telemedicine to provide access to OUD
pharmacotherapies. Barriers of time and distance
can limit access to OUD prescribers [11].
Buprenorphine prescribing physicians are often
clustered in urban centers [24]. Some behavioral
health organizations have begun to use telemedicine
to increase patient access to services that are not
available or if more capacity is needed in a given
clinic [33–35]. For buprenorphine care, a
buprenorphine prescriber can use videoconferencing
to treat a patient at a remote location. Resources
will be available in the PRB explaining how to use
telemedicine for buprenorphine care to increase
access to care and patient convenience.
f ) Promoting organizational leadership and culture to
support the building of OUD pharmacotherapy
capacity. Leadership and culture that supports use of
opioid treatment pharmacotherapies, and the
recruitment of OUD pharmacotherapy prescribers
facilitates provision of this evidence-based practice
[36]. Specific actions leaders can take to support recruitment include providing resources for recruiting
and creating an attractive environment for applicants
[37]. Examples of how to apply leadership skills to
promote medication-assisted treatment use will be
also included in the PRB.
In the intervention arm, the PRB implementation will
begin with a 4-month planning phase to identify practices
that are not present or underutilized in the study sites.
They will then be implemented in the rollout phase (Fig. 2).
Within each treatment organization, we will engage
management to participate in PRB practices: a top leader
(the executive sponsor), the primary physician recruiter for
the organization (the change leader) if different from the
executive sponsor, and the clinical director.
During the planning phase, key components of the PRB
implementation process (designed based on the evidencebased NIATx organizational change model [38, 39] include
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(1) defining the aim through a briefing between the executive sponsor and a project coach provided by the research
team, (2) assessing PRB baseline to measure level of use of
the different PRB practices and document the existing
buprenorphine slots availability and extended-release
naltrexone capacity, and (3) training leadership and
prescriber recruiters to develop and implement an
organizational change or a new practice from the bundle.
The training will include all organizations within the state
that were randomized to the intervention arm to encourage
cross-organizational sharing. After the planning phase, a
20-month rollout phase occurs that includes (4) monitoring
progress in increasing the number of buprenorphine slots,
extended-release naltrexone capacity, and use of the PRB;
(5) pilot testing of changes to implement and enhance PRB
implementation using the evidence-based Plan-Do-Check
(or measure)-Act approach [40]; and (6) sustaining successful changes by implementing a plan to institutionalize gains
and avoid reverting to the old system.
Throughout the planning and rollout phases, each
organization will have a coach. The coach is an expert in
prescriber recruitment, OUD treatment, and organizational
change who supports treatment organizations as they
make, sustain, and spread PRB practices. Coaches help
organizations think through key issues, offer process
improvement training, and suggest changes during monthly
coaching calls and e-mails as needed.
Timeline

During project months 1 to 18, the study team will
design the PRB intervention, complete IRB approval, and
identify and recruit treatment organizations. In months 14
to 18, the study team will collect baseline data on number
of assigned and open buprenorphine slots and extendedrelease naltrexone capacity. In months 15 to 42, the study
team will implement the study arm interventions and
collect outcome data on the 24-month staggered start intervention. During months 37 to 52, the study team will collect quantitative data on the sustainability of the changes.
Data analysis, publication development, and dissemination
of findings will occur at several points, but primarily during
months 53 to 60.
Sample size

In determining sample size, we fit a linear mixed-effects
model to the monthly results for assigned and available
buprenorphine slots to estimate the “PRB with NIATx
organizational change model” effect. The power of the
study design was determined by the anticipated
standardized effect size based on the effects experienced
in the PRB pilot study. The PRB pilot study, which
included 8 organizations, found that PRB increased
physician recruitment by 43.4–100%, which can be
transformed into Cohen’s d = .394 on average [41].
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Fig. 2 PRB implementation sequence (during the 24-month intervention period). OUD opioid use disorders, PRB Prescriber Recruitment Bundle,
MAT Medication-Assisted Therapy

Intraclass correlation (ICC) among sites affects the
power of cluster randomized trials [42]. The estimate of
ICC was around 0.10. We will have recruited 35 treatment sites and 35 comparison sites. Based on our previous and current projects with similar participants, we
expect about 15% attrition by the end of the data collection, so we used a more conservative 20% attrition rate
for our power calculations. With 28 organizations in
each condition with an average of 150 buprenorphine
slots in each organization, the study will achieve a power
of .93 (d = .30) or higher (d > .30) with a type I error
rate of 0.05. Power calculation for the cluster RCT was
performed using Optimal Design Software [43].
Data collection and measures

The primary outcome variables are the monthly number
of (a) assigned and (b) open buprenorphine slots as well
as (c) extended-release naltrexone capacity and (d)
administrations over the past month. Assigned slots are
defined as the number buprenorphine slots all prescribers affiliated with the organization have dedicated
to the organization. For the buprenorphine data, on the
first working Monday of the month, each organization
will count the numbers of assigned and open
buprenorphine slots. For extended-release naltrexone
data, the number of extended-release naltrexone administrations for the previous month will be counted. These
data will be collected during the 4-month planning
phase, the 20-month rollout phase, and the 10-month
sustainment phase, for a total of 34 months.
For the mediational analysis, at organizational baseline,
mid-intervention, and the end of the intervention
phases, the PRB change leader (or primary contact) will

complete the organizational surveys for the PRB implementation fidelity. In addition, any physician affiliated
with the organization (by employment or contract) will
complete the Physician Worklife Survey [21].
The qualitative portion of the study will support the
research questions by exploring facilitators and barriers to
successful prescriber recruitment, as well as the process of
PRB implementation within organizations and fidelity to
PRB implementation sequence. Sampling for the qualitative
component will promote integration of qualitative and
quantitative approaches by drawing upon findings from the
quantitative assessments. Semi-structured interviews will be
conducted with up to 15 organizations in the intervention
arm that have had success at implementing the PRB (at least
5 of the 7 practices from the PRB fidelity scale) and up to 15
organizations that have implemented fewer than 3 PRB
practices at the end of the first year or mid-point of
the intervention. In this longitudinal design, selected
organizations will be interviewed at end of the midpoint and at the end of the intervention period to
allow for more in-depth exploration of what occurred
within these organizations over time.
In the interviews, the closed-ended questions will be
based on domains of the Burke-Litwin Model of
Organizational Change: (1) leadership, (2) recruiting
practices, (3) work-unit change, and (4) organizational
motivational for recruitment [44]. The open-ended
questions will allow for discovery of other factors affecting PRB implementation and prescriber recruitment.
Data analysis

We intend to use an optimal design in which treatment
arms are allocated following a multi-site cluster
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randomization procedure [43]. A preliminary analysis
will compare baseline characteristics between intervention and control condition sites, as well as sites enrolled
in the project and eligible sites that chose to not participate. Chi-square tests and linear models will be used to
formally test for statistically significant baseline differences between the arms. Descriptive statistics and plots
will be used to summarize the distribution of each of the
analytic variables collected at each time point for each
arm. The organizational site is the unit of analysis.
For the primary outcome analysis, mixed-effects models
(random effects due to organization and fixed effects due
to study arm and time) will be used for data analysis of the
monthly number of assigned and open buprenorphine slots
per organization, estimated extended-release naltrexone
capacity, buprenorphine use, and extended-release naltrexone use. A number of organizational characteristics found
by Knudsen et al. [45] to affect the presence of physicians
in addiction treatment setting, including facility type,
services offered, and organizational size, will be included in
the models as covariates to properly and efficiently estimate
the effect of PRB. We will examine the PRB effect at each
time point using cross-sectional multilevel models and will
also implement growth curve models across time that
include the PRB effect, time, and PRB*time, as well as timevarying covariates and organizational characteristics. The
available and open buprenorphine slots, extended-release
naltrexone capacity, buprenorphine use, and extendedrelease naltrexone use will be measured repeatedly for the
same subjects, and it is expected that these values will be
correlated over time. Therefore, instead of assuming an
independence (i.e., zero correlation) or a compound
symmetry covariance structure (i.e., a constant correlation
regardless of the proximity of measurement time points),
we will allow errors to be auto-correlated or Toeplitz structured, denoted as AR(p) or TOEP(p), in the growth curve
models. This can be done by allowing additional parameters
in the mixed-effects model error structures that represent
the correlation between the adjacent measures of outcomes, and is reduced as the measures become further
apart [46]. For the meditational analysis, we will examine
the mediating effects of resources dedicated to physician
satisfaction and PRB implementation fidelity through a
causal mediational analysis. Each of the factors will be aggregated at the organizational site level and measured using
mixed-effects models. Through a mediation analysis [47,
48], we can estimate the direct (buprenorphine slots,
extended-release naltrexone, buprenorphine use, and
extended-release naltrexone use with and without PRB)
and indirect effects (resources dedicated to prescriber
recruitment, staff prescriber satisfaction, and PRB implementation fidelity) of the PRB on the outcome measures.
Using the R package “mediation,” we will estimate the
causal mediation effects, examine moderated mediation
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effects, and conduct sensitivity analysis at each time point
as well as across time [49].
The qualitative analysis will include deductive and
inductive components. The Burke-Litwin model will
provide the domains for a directed content analysis [50].
An inductive approach based on grounded theory and
dimensional analysis [51–54] will be used to identify and
explore additional contextual and processual factors that
affect PRB implementation. Both directed and inductive
analyses will include within-site and cross-site comparisons. Qualitative analysis will begin with the first interview and will continue in tandem with data collection,
allowing the investigators to use later interviews to delve
into factors identified in early interviews. Together, these
approaches will produce a thorough description of PRB
implementation that will be combined with the quantitative
results to deepen our understanding of how the PRB works,
promoting insights that can be applied to future dissemination of the PRB, and to discover strategies beyond the PRB
that contributed to prescriber recruitment.
Ethics

The study received approval from the institutional
review boards at the University of Wisconsin-Madison.
Trial status

The recruitment phase of the trial is nearly completed
and baseline data collection has begun.

Discussion
Opioid misuse has become a leading cause of substance
use disorder (SUD) admissions in the USA, second only
to alcohol misuse [55]. Traditionally, the most frequent
treatment for opioid disorders by specialty treatment
organizations has been behavioral therapy steeped in the
12-step tradition of Alcoholics Anonymous, which many
interpret as calling for an abstinence-only approach to
treatment that precludes the use of any medications
[56]. More recently, research has shown greater treatment retention rates and reduced use of illicit opioids
with pharmacotherapy compared to behavioral therapy
[3, 6, 57]. Hence, pharmacotherapy provides the most
promising therapy to treat those wanting to reduce the
adverse consequences of opioid misuse. The lack of
reimbursement for OUD pharmacotherapy [58],
philosophical resistance to pharmacotherapy to treat
SUDs [59], and limited availability of buprenorphine
prescribers inhibit use of buprenorphine in addiction
treatment settings [60]. The most widely endorsed
barrier among programs that do not use pharmacotherapy, however, is the lack of access to licensed prescribers
[61]. Increasing OUD pharmacotherapy prescribing
capacity is imperative in addressing the opioid epidemic.
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This trial addresses a structural barrier to use of
OUD pharmacotherapies, lack of OUD pharmacotherapy prescribing capacity. By increasing access to
evidence-based OUD pharmacotherapies, this trial
could have a significant public health impact by reducing the morbidity and mortality of opioid addiction.
Should the PRB be successful, it would, to our knowledge, be the first evidence-based prescriber recruiting
tool and could be used to recruit physicians and other
prescribers to medically underserved areas or other
areas where shortages exist.
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